Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.71 Million USD | -88.68% |
| 2022 | 5.61 Million USD | -38.52% |
| 2021 | 9.12 Million USD | -2.14% |
| 2020 | 9.32 Million USD | 116.33% |
| 2019 | 4.31 Million USD | 43.6% |
| 2018 | 3 Million USD | -78.31% |
| 2017 | 13.84 Million USD | 0.6% |
| 2016 | 13.75 Million USD | 0.56% |
| 2015 | 13.68 Million USD | 8.16% |
| 2014 | 12.65 Million USD | 51.04% |
| 2013 | 8.37 Million USD | 1.97% |
| 2012 | 8.21 Million USD | -23.0% |
| 2011 | 10.66 Million USD | -40.74% |
| 2010 | 17.99 Million USD | -42.23% |
| 2009 | 31.15 Million USD | 20.05% |
| 2008 | 25.95 Million USD | 16.46% |
| 2007 | 22.28 Million USD | 24.39% |
| 2006 | 17.91 Million USD | 37.3% |
| 2005 | 13.04 Million USD | 24.43% |
| 2004 | 10.48 Million USD | 12.55% |
| 2003 | 9.31 Million USD | -26.28% |
| 2002 | 12.63 Million USD | 6.42% |
| 2001 | 11.87 Million USD | 8.09% |
| 2000 | 10.98 Million USD | -6.64% |
| 1999 | 11.76 Million USD | -13.46% |
| 1998 | 13.6 Million USD | 30.77% |
| 1997 | 10.4 Million USD | 57.58% |
| 1996 | 6.6 Million USD | 60.98% |
| 1995 | 4.1 Million USD | 32.26% |
| 1994 | 3.1 Million USD | 47.62% |
| 1993 | 2.1 Million USD | 31.25% |
| 1992 | 1.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 167.22 Thousand USD | 47.38% |
| 2024 Q2 | 96.58 Thousand USD | -42.24% |
| 2023 Q4 | 113.46 Thousand USD | 104.36% |
| 2023 FY | 634.86 Thousand USD | -88.68% |
| 2023 Q3 | 55.52 Thousand USD | -76.75% |
| 2023 Q2 | 238.75 Thousand USD | -9.6% |
| 2023 Q1 | 264.11 Thousand USD | -36.3% |
| 2022 Q3 | 595.43 Thousand USD | 132.31% |
| 2022 Q4 | 414.61 Thousand USD | -30.37% |
| 2022 Q1 | 4.34 Million USD | 186.78% |
| 2022 Q2 | 256.31 Thousand USD | -94.1% |
| 2022 FY | 5.61 Million USD | -38.52% |
| 2021 Q4 | 1.51 Million USD | -16.26% |
| 2021 Q2 | 3.76 Million USD | 84.71% |
| 2021 FY | 9.12 Million USD | -2.14% |
| 2021 Q3 | 1.8 Million USD | -51.94% |
| 2021 Q1 | 2.03 Million USD | -38.84% |
| 2020 Q3 | 1.61 Million USD | 16.6% |
| 2020 FY | 9.32 Million USD | 116.33% |
| 2020 Q1 | 2.98 Million USD | 140.49% |
| 2020 Q2 | 1.38 Million USD | -53.63% |
| 2020 Q4 | 3.33 Million USD | 106.15% |
| 2019 Q2 | 1.16 Million USD | 83.12% |
| 2019 Q1 | 634 Thousand USD | 0.79% |
| 2019 FY | 4.31 Million USD | 43.6% |
| 2019 Q4 | 1.24 Million USD | 33.56% |
| 2019 Q3 | 930.71 Thousand USD | -19.84% |
| 2018 Q4 | 629 Thousand USD | -7.5% |
| 2018 Q2 | 898 Thousand USD | 12.96% |
| 2018 FY | 3 Million USD | -78.31% |
| 2018 Q1 | 795 Thousand USD | -67.36% |
| 2018 Q3 | 680 Thousand USD | -24.28% |
| 2017 Q1 | 3.97 Million USD | 14.24% |
| 2017 FY | 13.84 Million USD | 0.6% |
| 2017 Q4 | 2.43 Million USD | -31.19% |
| 2017 Q3 | 3.54 Million USD | -9.14% |
| 2017 Q2 | 3.89 Million USD | -1.86% |
| 2016 Q3 | 3.26 Million USD | -11.12% |
| 2016 Q4 | 3.47 Million USD | 6.53% |
| 2016 FY | 13.75 Million USD | 0.56% |
| 2016 Q1 | 3.35 Million USD | -15.74% |
| 2016 Q2 | 3.67 Million USD | 9.49% |
| 2015 Q1 | 2.77 Million USD | 4.99% |
| 2015 Q4 | 3.97 Million USD | 10.53% |
| 2015 FY | 13.68 Million USD | 8.16% |
| 2015 Q2 | 3.32 Million USD | 19.84% |
| 2015 Q3 | 3.59 Million USD | 8.14% |
| 2014 Q3 | 3.45 Million USD | -12.0% |
| 2014 Q1 | 2.62 Million USD | 25.32% |
| 2014 FY | 12.65 Million USD | 51.04% |
| 2014 Q2 | 3.92 Million USD | 49.32% |
| 2014 Q4 | 2.64 Million USD | -23.4% |
| 2013 Q3 | 2.74 Million USD | 65.68% |
| 2013 Q1 | 1.88 Million USD | 9.81% |
| 2013 Q4 | 2.09 Million USD | -23.52% |
| 2013 Q2 | 1.65 Million USD | -12.01% |
| 2013 FY | 8.37 Million USD | 1.97% |
| 2012 FY | 8.21 Million USD | -23.0% |
| 2012 Q1 | 1.98 Million USD | -13.31% |
| 2012 Q2 | 2.27 Million USD | 14.75% |
| 2012 Q3 | 2.23 Million USD | -1.93% |
| 2012 Q4 | 1.71 Million USD | -23.36% |
| 2011 Q1 | 3.06 Million USD | -11.07% |
| 2011 FY | 10.66 Million USD | -40.74% |
| 2011 Q4 | 2.29 Million USD | -4.82% |
| 2011 Q3 | 2.4 Million USD | -17.0% |
| 2011 Q2 | 2.9 Million USD | -5.48% |
| 2010 FY | 17.99 Million USD | -42.23% |
| 2010 Q2 | 5.02 Million USD | -14.64% |
| 2010 Q1 | 5.88 Million USD | -31.6% |
| 2010 Q3 | 3.63 Million USD | -27.68% |
| 2010 Q4 | 3.45 Million USD | -5.09% |
| 2009 Q3 | 7.74 Million USD | -5.32% |
| 2009 Q2 | 8.17 Million USD | 23.25% |
| 2009 FY | 31.15 Million USD | 20.05% |
| 2009 Q1 | 6.63 Million USD | 14.78% |
| 2009 Q4 | 8.6 Million USD | 11.21% |
| 2008 Q3 | 7.23 Million USD | 0.54% |
| 2008 Q1 | 5.73 Million USD | -6.88% |
| 2008 FY | 25.95 Million USD | 16.46% |
| 2008 Q4 | 5.77 Million USD | -20.16% |
| 2008 Q2 | 7.19 Million USD | 25.48% |
| 2007 Q4 | 6.16 Million USD | 7.54% |
| 2007 Q3 | 5.72 Million USD | -2.6% |
| 2007 FY | 22.28 Million USD | 24.39% |
| 2007 Q1 | 4.51 Million USD | 12.88% |
| 2007 Q2 | 5.88 Million USD | 30.33% |
| 2006 FY | 17.91 Million USD | 37.3% |
| 2006 Q4 | 3.99 Million USD | -8.39% |
| 2006 Q3 | 4.36 Million USD | -22.24% |
| 2006 Q2 | 5.61 Million USD | 42.36% |
| 2006 Q1 | 3.94 Million USD | 6.43% |
| 2005 Q1 | 2.21 Million USD | -3.15% |
| 2005 Q3 | 3.76 Million USD | 11.85% |
| 2005 Q4 | 3.7 Million USD | -1.62% |
| 2005 FY | 13.04 Million USD | 24.43% |
| 2005 Q2 | 3.36 Million USD | 52.03% |
| 2004 Q1 | 2.21 Million USD | -10.88% |
| 2004 FY | 10.48 Million USD | 12.55% |
| 2004 Q4 | 2.28 Million USD | -24.95% |
| 2004 Q3 | 3.04 Million USD | 3.54% |
| 2004 Q2 | 2.94 Million USD | 33.0% |
| 2003 Q1 | 1.48 Million USD | -41.23% |
| 2003 Q3 | 3.42 Million USD | 82.62% |
| 2003 Q2 | 1.87 Million USD | 26.08% |
| 2003 FY | 9.31 Million USD | -26.28% |
| 2003 Q4 | 2.48 Million USD | -27.55% |
| 2002 Q3 | 1.74 Million USD | -37.78% |
| 2002 Q1 | 5.55 Million USD | 57.85% |
| 2002 FY | 12.63 Million USD | 6.42% |
| 2002 Q4 | 2.53 Million USD | 45.19% |
| 2002 Q2 | 2.8 Million USD | -49.58% |
| 2001 Q4 | 3.52 Million USD | 54.73% |
| 2001 Q1 | 2.55 Million USD | 19.1% |
| 2001 Q3 | 2.27 Million USD | -36.19% |
| 2001 Q2 | 3.56 Million USD | 39.61% |
| 2001 FY | 11.87 Million USD | 8.09% |
| 2000 Q4 | 2.14 Million USD | -40.04% |
| 2000 Q2 | 2.27 Million USD | -30.13% |
| 2000 FY | 10.98 Million USD | -6.64% |
| 2000 Q1 | 3.25 Million USD | 6.08% |
| 2000 Q3 | 3.57 Million USD | 57.27% |
| 1999 Q3 | 3.7 Million USD | 32.14% |
| 1999 Q2 | 2.8 Million USD | 21.74% |
| 1999 Q1 | 2.3 Million USD | -42.5% |
| 1999 FY | 11.76 Million USD | -13.46% |
| 1999 Q4 | 3.06 Million USD | -17.05% |
| 1998 Q3 | 3.9 Million USD | 18.18% |
| 1998 Q4 | 4 Million USD | 2.56% |
| 1998 Q1 | 2.5 Million USD | -19.35% |
| 1998 Q2 | 3.3 Million USD | 32.0% |
| 1998 FY | 13.6 Million USD | 30.77% |
| 1997 Q2 | 3 Million USD | 36.36% |
| 1997 FY | 10.4 Million USD | 57.58% |
| 1997 Q4 | 3.1 Million USD | 40.91% |
| 1997 Q3 | 2.2 Million USD | -26.67% |
| 1997 Q1 | 2.2 Million USD | 29.41% |
| 1996 Q1 | 1.6 Million USD | 139.02% |
| 1996 Q2 | 2 Million USD | 25.0% |
| 1996 Q3 | 1.3 Million USD | -35.0% |
| 1996 Q4 | 1.7 Million USD | 30.77% |
| 1996 FY | 6.6 Million USD | 60.98% |
| 1995 Q2 | 800 Thousand USD | -27.27% |
| 1995 Q4 | -4.1 Million USD | 0.0% |
| 1995 Q3 | - USD | -100.0% |
| 1995 FY | 4.1 Million USD | 32.26% |
| 1995 Q1 | 1.1 Million USD | 135.48% |
| 1994 Q3 | - USD | -100.0% |
| 1994 Q2 | 600 Thousand USD | 0.0% |
| 1994 Q1 | - USD | -100.0% |
| 1994 FY | 3.1 Million USD | 47.62% |
| 1994 Q4 | -3.1 Million USD | 0.0% |
| 1993 Q1 | - USD | 100.0% |
| 1993 Q3 | 200 Thousand USD | 0.0% |
| 1993 Q4 | 1.2 Million USD | 500.0% |
| 1993 FY | 2.1 Million USD | 31.25% |
| 1993 Q2 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q4 | -1.6 Million USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 FY | 1.6 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -403.06% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -33.24% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 77.268% |
| Nascent Biotech, Inc. | 2.22 Million USD | -201.273% |
| Rebus Holdings, Inc. | 664 Thousand USD | -911.749% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 81.968% |
| Qrons Inc. | 643.67 Thousand USD | -943.693% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1624.487% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 88.304% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1516.933% |
| Skye Bioscience, Inc. | 13.54 Million USD | 50.412% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 92.259% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -36.603% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2466.812% |
| SQZ Biotechnologies Company | 85.61 Million USD | 92.154% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -130.366% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -347.301% |
| Mesoblast Limited | 5.9 Million USD | -13.826% |
| Marizyme, Inc. | 19.23 Million USD | 65.083% |
| Genus plc | 147.7 Million USD | 95.452% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 23.478% |
| Pharming Group N.V. | 225.49 Million USD | 97.021% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -227.915% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -400.767% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 19.439% |
| ContraFect Corporation | 56.88 Million USD | 88.191% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -52.382% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -354.303% |
| IMV Inc. | 37.7 Million USD | 82.185% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -140.758% |
| MultiCell Technologies, Inc. | 567.42 USD | -1183858.091% |
| ONE Bio Corp. | 6.44 Million USD | -4.254% |
| Accustem Sciences Inc. | 3.74 Million USD | -79.318% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 92.183% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1162.875% |
| Q BioMed Inc. | 3.43 Million USD | -95.483% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 72.818% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -155.679% |
| Biomind Labs Inc. | 994.18 Thousand USD | -575.733% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 93.237% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -281.775% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -260.337% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 26972.06% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 58.039% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -266.085% |
| GB Sciences, Inc. | 1.42 Million USD | -372.93% |
| Alpha Cognition Inc. | 9.7 Million USD | 30.782% |
| HST Global, Inc. | 140.9 Thousand USD | -4667.694% |
| CSL Limited | 3.44 Billion USD | 99.805% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -497.205% |
| Halberd Corporation | 74.84 Thousand USD | -8876.263% |
| Enzolytics Inc. | 2.17 Million USD | -208.236% |
| Agentix Corp. | 1.37 Million USD | -389.738% |
| Resverlogix Corp. | 12.71 Million USD | 47.152% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -84.02% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.562% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -543.488% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -179.343% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -325.364% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -97.3% |
| AVAX Technologies, Inc. | 7.31 Million USD | 8.102% |
| Zenith Capital Corp. | 8.94 Million USD | 24.88% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.186% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -38462.74% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -173.611% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -3817.004% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -249.732% |
| Kadimastem Ltd | 2.41 Million USD | -178.743% |
| Helix BioMedix, Inc. | 1.97 Million USD | -240.664% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 38.18% |
| BioStem Technologies, Inc. | 22.97 Million USD | 70.759% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -3601.692% |
| LadRx Corporation | 3.81 Million USD | -76.243% |
| Cell Source, Inc. | 4.32 Million USD | -55.317% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -627.444% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -627.444% |
| NovAccess Global Inc. | 2.46 Million USD | -172.342% |
| Affymax, Inc. | 39.38 Million USD | 82.943% |
| Itoco Inc. | 919.14 Thousand USD | -630.9% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -58.503% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -500.359% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1111.444% |
| CytoDyn Inc. | 18.05 Million USD | 62.798% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -26591.625% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2952.561% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -373.169% |
| SYBLEU INC | 160.87 Thousand USD | -4075.896% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -269.87% |
| International Stem Cell Corporation | 5.27 Million USD | -27.452% |
| Bioxytran, Inc. | 3.82 Million USD | -75.857% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -12661.702% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -32923.718% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 81.476% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -315.205% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -812.978% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -115.944% |
| Neutra Corp. | 243.82 Thousand USD | -2655.306% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 61.517% |
| PureTech Health plc | 144.59 Million USD | 95.354% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 67.213% |
| IXICO plc | 4.7 Million USD | -42.724% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 23.633% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 94.295% |
| CSL Limited | 3.89 Billion USD | 99.827% |
| Cellectis S.A. | 97.32 Million USD | 93.097% |